In patients with RA, TNF inhibitor use during the 3 years after being diagnosed with early-stage lung, colorectal, or prostate cancer was not linked to decreased survival.

One more systematic study from Japan, with 163 RA patients, found that ILD was ... respiratory hospitalization occurred in 43% of the TNF inhibitor group over 3 years of follow-up, versus 47% ...

TNF has emerged as an important factor in the pathogenesis of RA, and the inhibition of TNF signaling has proven to be a highly effective therapeutic strategy for this and other diseases.

Janus kinase (JAK) inhibitors are associated with an increased risk for lung cancer but not overall cancer among older patients in the United States with rheumatoid arthritis (RA), according to study ...

Perspective from Devin Weidman, MSN, APRN-C TNF inhibitor use demonstrates no negative ... The study included 1,981 patients with RA split into three different groups — those with early-stage ...

It was the first partially selective TACE inhibitor to reach phase II clinical trials for the treatment of RA and was tested in the preclinical setting for inflammatory bowel disease. BMS has ...

announced that data from the Phase 2a clinical trial of its oral TNF-alpha (TNF-α) inhibitor drug candidate isomyosamine was presented last week in a podium session at the peer-reviewed 15th ...

announced that data from the Phase 2a clinical trial of its oral TNF-alpha (TNF-α) inhibitor drug candidate isomyosamine was presented last week in a podium session at the peer-reviewed 15th ...